

Attorney Docket: ARC 3036 R1
Preliminary Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 38. (New) A method of transdermally delivering a pharmacologically active agent to a patient, comprising the steps of:

providing a microprotrusion member having a plurality of stratum corneum-piercing microprotrusions, said microprotrusion member having a coating disposed thereon, said coating including at least one pharmacologically active agent, said pharmacologically active agent being sufficiently potent to be therapeutically effective when administered in an amount less than about 1 mg; and

applying said microprotrusion member to a skin site on the patient, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said pharmacologically active agent to the patient,

wherein said delivered pharmacologically active agent has improved pharmacokinetics compared to pharmacokinetics after subcutaneous injection.

Claim 39. (New) The method of Claim 46, wherein said pharmacologically active agent is selected from the group consisting of ACTH(1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, PTH, vasopressin, deamino[Val4, D-Arg8] arginine vasopressin, buscrelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF), and analogs and pharmaceutically acceptable salts thereof.

Claim 40. (New) The method of Claim 38, wherein said improved pharmacokinetics comprises increased bioavailability of said pharmacologically active agent.

Claim 41. (New) The method of Claim 38, wherein said improved pharmacokinetics comprises an increase in C_{max} .

Claim 42. (New) The method of Claim 38, wherein said improved pharmacokinetics comprises a decrease in T_{max} .

Claim 43. (New) The method of Claim 38, wherein said improved pharmacokinetics comprises an enhanced absorption rate of said pharmacologically active agent.

Attorney Docket: ARC 3036 R1
Preliminary Amendment

Claim 44. (New) The method of Claim 38, wherein said coating is formed from an aqueous solution having solubility greater than approximately 50 mg/ml.

Claim 45. (New) The method of Claim 44, wherein said aqueous solution has a viscosity less than approximately 500 centipoises.

Claim 46. (New) The method of Claim 38, wherein each of said plurality of stratum corneum-piercing microprotrusions has a length less than approximately 500 microns.